CR20120081A - Inhibidores de los virus flaviviridae - Google Patents
Inhibidores de los virus flaviviridaeInfo
- Publication number
- CR20120081A CR20120081A CR20120081A CR20120081A CR20120081A CR 20120081 A CR20120081 A CR 20120081A CR 20120081 A CR20120081 A CR 20120081A CR 20120081 A CR20120081 A CR 20120081A CR 20120081 A CR20120081 A CR 20120081A
- Authority
- CR
- Costa Rica
- Prior art keywords
- flaviviridae virus
- virus inhibitors
- optionally substituted
- formula
- inhibitors
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
- C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
- C07D333/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems
Abstract
A continuación se proporcionan los compuestos de la Fórmula o una sal o un éster aceptables desde el punto de vista armacéutico de dicha fórmula, donde:R1 se selecciona del grupo que consiste en C1-12 alquilo opcionalmente sustituido, C2-12 alquenilo opcionalmente sustituido, C2-12 alquinilo opcionalmente sustituido.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US22736709P | 2009-07-21 | 2009-07-21 | |
US24091109P | 2009-09-09 | 2009-09-09 | |
US35946610P | 2010-06-29 | 2010-06-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
CR20120081A true CR20120081A (es) | 2012-07-04 |
Family
ID=42711860
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CR20120081A CR20120081A (es) | 2009-07-21 | 2012-02-16 | Inhibidores de los virus flaviviridae |
Country Status (26)
Country | Link |
---|---|
US (2) | US8569302B2 (es) |
EP (1) | EP2475657B1 (es) |
JP (2) | JP5841531B2 (es) |
KR (1) | KR20120051022A (es) |
CN (1) | CN102471327A (es) |
AP (1) | AP3409A (es) |
AR (1) | AR077765A1 (es) |
AU (1) | AU2010276441B2 (es) |
CA (1) | CA2767088C (es) |
CL (1) | CL2012000147A1 (es) |
CO (1) | CO6491049A2 (es) |
CR (1) | CR20120081A (es) |
DK (1) | DK2475657T3 (es) |
EA (1) | EA020816B1 (es) |
EC (1) | ECSP12011684A (es) |
ES (1) | ES2427342T3 (es) |
HK (1) | HK1166788A1 (es) |
IL (1) | IL217243A (es) |
MX (1) | MX2012000959A (es) |
NZ (1) | NZ597528A (es) |
PE (1) | PE20120666A1 (es) |
SG (1) | SG177709A1 (es) |
TW (1) | TW201116525A (es) |
UY (1) | UY32793A (es) |
WO (1) | WO2011011303A1 (es) |
ZA (1) | ZA201200940B (es) |
Families Citing this family (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR077765A1 (es) * | 2009-07-21 | 2011-09-21 | Gilead Sciences Inc | Inhibidores de los virus flaviviridae |
JP5774008B2 (ja) | 2009-09-09 | 2015-09-02 | ギリアード サイエンシーズ, インコーポレイテッド | Flaviviridaeウイルスの阻害剤 |
ME01528B (me) | 2009-09-21 | 2014-04-20 | Gilead Sciences Inc | POSTUPCI l INTERMEDIJERI ZA PROIZVODNJU 1'-CIJANOKARBANUKLEOZIDIH ANALOGA |
CA2785563C (en) | 2010-01-15 | 2019-05-14 | Gilead Sciences, Inc. | Inhibitors of flaviviridae viruses |
PT2523950T (pt) * | 2010-01-15 | 2017-06-01 | Gilead Sciences Inc | Inibidores dos vírus flaviridae |
EP2585447A2 (en) * | 2010-06-28 | 2013-05-01 | Vertex Pharmaceuticals Incorporated | Compounds and methods for the treatment or prevention of flavivirus infections |
AU2011281546B2 (en) * | 2010-07-22 | 2014-07-10 | Novartis Ag | 2,3,5-trisubstituted thiophene compounds and uses thereof |
MX2013000744A (es) | 2010-07-22 | 2013-03-07 | Gilead Sciences Inc | Metodos y compuestos para tratar infecciones virales por paramyxoviridae. |
ES2561888T3 (es) * | 2011-07-13 | 2016-03-01 | Gilead Sciences, Inc. | Derivados de ácido tiofeno-2-carboxílico útiles como inhibidores de virus Flaviviridae |
PE20150154A1 (es) | 2012-06-26 | 2015-02-19 | Bayer Pharma AG | N-[4-(quinolin-4-iloxi)ciclohexil(metil)](hetero)arilcarboxamidas como antagonistas del receptor de androgenos, su produccion y usos como productos medicinales |
US8759544B2 (en) * | 2012-08-17 | 2014-06-24 | Gilead Sciences, Inc. | Synthesis of an antiviral compound |
US8841340B2 (en) | 2012-08-17 | 2014-09-23 | Gilead Sciences, Inc. | Solid forms of an antiviral compound |
US8927741B2 (en) | 2012-08-17 | 2015-01-06 | Gilead Sciences, Inc. | Synthesis of an antiviral compound |
CN102964295B (zh) * | 2012-12-17 | 2014-08-20 | 寿光富康制药有限公司 | 一种2-取代-4-(哌啶基甲基)吡啶的制备方法 |
EP2762124A1 (en) * | 2013-01-31 | 2014-08-06 | IP Gesellschaft für Management mbH | Packaging comprising administration units of polymorphs, amorphous forms or solvates |
US9492438B2 (en) * | 2014-07-25 | 2016-11-15 | Bette Pollard | Amphiphilic pyridinum compounds to treat epilepsy and other disorders of the nervous system |
TWI687432B (zh) | 2014-10-29 | 2020-03-11 | 美商基利科學股份有限公司 | 絲狀病毒科病毒感染之治療 |
HRP20211456T1 (hr) | 2014-12-26 | 2021-12-24 | Emory University | Protuvirusni derivati n4-hidroksicitidina |
MA52371A (fr) | 2015-09-16 | 2021-09-22 | Gilead Sciences Inc | Méthodes de traitement d'infections dues aux coronaviridae |
WO2017197046A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | C3-carbon linked glutarimide degronimers for target protein degradation |
CN109562113A (zh) | 2016-05-10 | 2019-04-02 | C4医药公司 | 用于靶蛋白降解的螺环降解决定子体 |
EP3454856A4 (en) | 2016-05-10 | 2019-12-25 | C4 Therapeutics, Inc. | HETEROCYCLIC DEGRONIMERS FOR TARGET PROTEIN REDUCTION |
JP2019525947A (ja) | 2016-06-01 | 2019-09-12 | エムスリー・バイオテクノロジー・インコーポレイテッドM3 Biotechnology, Inc. | 化合物 |
CA3056072C (en) | 2017-03-14 | 2022-08-23 | Gilead Sciences, Inc. | Methods of treating feline coronavirus infections |
CN110636884B (zh) | 2017-05-01 | 2022-10-04 | 吉利德科学公司 | 新结晶形式 |
WO2019014247A1 (en) | 2017-07-11 | 2019-01-17 | Gilead Sciences, Inc. | COMPOSITIONS COMPRISING POLYMERASE RNA INHIBITOR AND CYCLODEXTRIN FOR THE TREATMENT OF VIRAL INFECTIONS |
US11331331B2 (en) | 2017-12-07 | 2022-05-17 | Emory University | N4-hydroxycytidine and derivatives and anti-viral uses related thereto |
AU2021214911A1 (en) | 2020-01-27 | 2022-07-21 | Gilead Sciences, Inc. | Methods for treating SARS CoV-2 infections |
CA3169340A1 (en) | 2020-03-12 | 2021-09-16 | Pavel R. Badalov | Methods of preparing 1'-cyano nucleosides |
AU2021251689A1 (en) | 2020-04-06 | 2022-11-17 | Gilead Sciences, Inc. | Inhalation formulations of 1'-cyano substituted carbanucleoside analogs |
JP2023528810A (ja) | 2020-05-29 | 2023-07-06 | ギリアード サイエンシーズ, インコーポレイテッド | レムデシビル治療方法 |
US11939347B2 (en) | 2020-06-24 | 2024-03-26 | Gilead Sciences, Inc. | 1′-cyano nucleoside analogs and uses thereof |
EP4204421A2 (en) | 2020-08-27 | 2023-07-05 | Gilead Sciences, Inc. | Compounds and methods for treatment of viral infections |
US11351149B2 (en) | 2020-09-03 | 2022-06-07 | Pfizer Inc. | Nitrile-containing antiviral compounds |
US20230295172A1 (en) | 2022-03-02 | 2023-09-21 | Gilead Sciences, Inc. | Compounds and methods for treatment of viral infections |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5861421A (en) | 1995-12-21 | 1999-01-19 | Smithkline Beecham Corporation | 4,4-(disubstituted) cyclohexan-1-one monomers and related compounds |
US20020002199A1 (en) * | 1998-03-12 | 2002-01-03 | Lone Jeppesen | Modulators of protein tyrosine phosphatases (ptpases) |
US20050119332A1 (en) * | 1998-03-12 | 2005-06-02 | Lone Jeppesen | Substituted thiophene compounds as modulators of protein tyrosine phosphatases (PTPases) |
SK288015B6 (sk) * | 2001-06-11 | 2012-11-05 | Virochem Pharma Inc. | Thiophene derivatives as antiviral agents for flavivirus infection |
CA2449999C (en) * | 2001-06-11 | 2012-07-31 | Shire Biochem Inc. | Compounds and methods for the treatment or prevention of flavivirus infections |
PT1569929E (pt) * | 2002-12-10 | 2010-06-18 | Virochem Pharma Inc | Compostos e métodos para o tratamento ou prevenção de infecções por flavivírus |
MXPA05006196A (es) | 2002-12-10 | 2006-01-27 | Virochem Pharma Inc | Compuestos y metodos para el tratamiento o prevencion de infecciones por flavivirus. |
DE10359791A1 (de) * | 2003-12-19 | 2005-07-21 | Bayer Healthcare Ag | Substituierte Thiophene |
US7521473B2 (en) * | 2004-02-25 | 2009-04-21 | Wyeth | Inhibitors of protein tyrosine phosphatase 1B |
CN1989131A (zh) * | 2004-03-30 | 2007-06-27 | 希龙公司 | 取代的噻吩衍生物用作抗癌药 |
DE102005028077A1 (de) | 2004-12-22 | 2006-07-13 | Aicuris Gmbh & Co. Kg | Alkinyl-substituierte Thiophene |
DE102004061746A1 (de) * | 2004-12-22 | 2006-07-06 | Bayer Healthcare Ag | Alkinyl-substituierte Thiophene |
NZ563909A (en) * | 2005-05-13 | 2011-10-28 | Virochem Pharma Inc | Thiophene derivatives and their use for the treatment or prevention of flavivirus infections |
WO2007093365A2 (en) * | 2006-02-15 | 2007-08-23 | Sanofi-Aventis | Novel amino alcohol-substituted arylthienopyrimidinones, process for their preparation and their use as medicaments |
CA2670260A1 (en) * | 2006-11-15 | 2008-05-22 | Virochem Pharma Inc. | Thiophene analogues for the treatment or prevention of flavivirus infections |
EP2086966B1 (en) * | 2006-11-17 | 2011-09-14 | GlaxoSmithKline LLC | 2-carboxy thiophene derivatives as anti viral agents |
WO2010065681A1 (en) | 2008-12-03 | 2010-06-10 | Presidio Pharmaceuticals, Inc. | Inhibitors of hcv ns5a |
AR077765A1 (es) * | 2009-07-21 | 2011-09-21 | Gilead Sciences Inc | Inhibidores de los virus flaviviridae |
JP5774008B2 (ja) * | 2009-09-09 | 2015-09-02 | ギリアード サイエンシーズ, インコーポレイテッド | Flaviviridaeウイルスの阻害剤 |
CA2781614A1 (en) | 2009-11-25 | 2011-06-09 | Vertex Pharmaceuticals Incorporated | 5-alkynyl-thiophene-2-carboxylic acid derivatives and their use for the treatment or prevention of flavivirus infections |
CA2785563C (en) * | 2010-01-15 | 2019-05-14 | Gilead Sciences, Inc. | Inhibitors of flaviviridae viruses |
PT2523950T (pt) * | 2010-01-15 | 2017-06-01 | Gilead Sciences Inc | Inibidores dos vírus flaviridae |
EP2585447A2 (en) | 2010-06-28 | 2013-05-01 | Vertex Pharmaceuticals Incorporated | Compounds and methods for the treatment or prevention of flavivirus infections |
-
2010
- 2010-07-19 AR ARP100102629A patent/AR077765A1/es unknown
- 2010-07-19 CA CA2767088A patent/CA2767088C/en not_active Expired - Fee Related
- 2010-07-19 US US12/838,684 patent/US8569302B2/en active Active
- 2010-07-19 EA EA201290053A patent/EA020816B1/ru not_active IP Right Cessation
- 2010-07-19 SG SG2012004115A patent/SG177709A1/en unknown
- 2010-07-19 CN CN2010800328463A patent/CN102471327A/zh active Pending
- 2010-07-19 WO PCT/US2010/042394 patent/WO2011011303A1/en active Application Filing
- 2010-07-19 TW TW099123657A patent/TW201116525A/zh unknown
- 2010-07-19 ES ES10735402T patent/ES2427342T3/es active Active
- 2010-07-19 KR KR1020127004379A patent/KR20120051022A/ko not_active Application Discontinuation
- 2010-07-19 AP AP2012006085A patent/AP3409A/xx active
- 2010-07-19 UY UY0001032793A patent/UY32793A/es not_active Application Discontinuation
- 2010-07-19 AU AU2010276441A patent/AU2010276441B2/en not_active Ceased
- 2010-07-19 DK DK10735402.9T patent/DK2475657T3/da active
- 2010-07-19 JP JP2012521700A patent/JP5841531B2/ja not_active Expired - Fee Related
- 2010-07-19 EP EP10735402.9A patent/EP2475657B1/en active Active
- 2010-07-19 NZ NZ597528A patent/NZ597528A/en not_active IP Right Cessation
- 2010-07-19 MX MX2012000959A patent/MX2012000959A/es active IP Right Grant
- 2010-07-19 PE PE2012000069A patent/PE20120666A1/es not_active Application Discontinuation
-
2011
- 2011-12-28 IL IL217243A patent/IL217243A/en not_active IP Right Cessation
-
2012
- 2012-01-17 CO CO12006267A patent/CO6491049A2/es active IP Right Grant
- 2012-01-19 CL CL2012000147A patent/CL2012000147A1/es unknown
- 2012-02-08 ZA ZA2012/00940A patent/ZA201200940B/en unknown
- 2012-02-16 CR CR20120081A patent/CR20120081A/es unknown
- 2012-02-16 EC ECSP12011684 patent/ECSP12011684A/es unknown
- 2012-07-27 HK HK12107401.4A patent/HK1166788A1/xx unknown
-
2013
- 2013-09-25 US US14/037,296 patent/US20140030223A1/en not_active Abandoned
-
2015
- 2015-08-18 JP JP2015160807A patent/JP2015205940A/ja not_active Withdrawn
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CR20120081A (es) | Inhibidores de los virus flaviviridae | |
CY2020032I1 (el) | Παραγωγα πλευρομουτιλινης για τη θεραπεια ασθενειων που προκαλουνται απο μικροβια | |
CL2012001911A1 (es) | Compuestos derivados de fumarato; composicion farmaceutica que los comprende; y su uso en el tratamiento de una enfermedad inflamatoria o neurodegenerativa. | |
ECSP12012103A (es) | Inhibidores de virus flaviviridae. | |
CU24039B1 (es) | Derivados de imidazolidin-2-ona 1,3-disustituida como inhibidores de cyp17 | |
CO6620055A2 (es) | Ciertas amino-pirimidinas, composiciones de las mismas y métodos para el uso de los mismos | |
UY32490A (es) | Inhibidores de beta-secretasa | |
UY35126A (es) | Ojo es alfa | |
CR20140294A (es) | Derivados de dihidro-benzo-oxazina y dihidro-pirido-oxazina | |
GT201200230A (es) | Inhibidores del virus de la hepatitis c | |
ECSP12012104A (es) | Inhibidores de virus flaviviridae | |
PE20141558A1 (es) | Derivados de acido benzotiazol-6-il acetico y su uso para tratar una infeccion por vih | |
UY33775A (es) | Inhibidores macrocíclicos de virus flaviviridae, composiciones farmacéuticas que los comprenden y sus usos | |
RS54386B1 (en) | ANTIVIRAL UNITS | |
AR093659A1 (es) | Derivados ciclicos de nucleosidos y usos de los mismos | |
RS54526B1 (en) | USE OF PIRAZOLOSPIROKETONE DERIVATIVES AS ACETYL-COA CARBOXYLASE INHIBITORS | |
ES2657549T3 (es) | Piridopirazinas sustituidas como nuevos inhibidores de SYK | |
AR112787A2 (es) | Compuestos 1,5-difenil-penta-1,4-dien-3-ona | |
DK2155731T3 (da) | 1,3-Dihydroimidazol-2-thion-derivater som inhibitorer af dopamin-beta-hydroxylase | |
AR081725A1 (es) | Derivados de oxadiazol, proceso de preparacion de los mismos, composicion farmaceutica que los contienen y su uso en el tratamiento del cancer | |
JO3143B1 (ar) | مركبات تتراهيدرو بيرولو ثيازين | |
CL2012000278A1 (es) | Proceso para la obtencion de derivados de 5-trifluorometil-pirimidinas; y uno de los compuestos intermediarios considerados. | |
ES2572508T3 (es) | Derivados de orvinol y de tevinol útiles en el tratamiento de la drogodependencia y del alcoholismo | |
UY31824A (es) | Nuevos compuestos | |
AR077429A1 (es) | Compuestos hidroxiasenapina sus derivados y composiciones farmaceuticas que comprenden los mismos |